Cytek Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Cytek Biosciences

05/08/2026 23:44

Cytek Biosciences, Inc. CTKB.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -4 cents.  The mean expectation of four analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -9 cents to -8 cents per share.
Revenue rose 5.6% to $48.14 million from a year ago; analysts expected $48.61 million. 
Cytek Biosciences, Inc.'s reported EPS for the quarter was a loss of 9 cents​.
The company reported a quarterly loss of $12.16 million.
Cytek Biosciences, Inc. shares had fallen by 3.4% this quarter and lost 15.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 21.4% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Cytek Biosciences, Inc. is $5.25, about 18.5% above its last closing price of $4.28
This summary was machine generated from LSEG data August 5 at 10:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.08
-0.08
Met
Mar. 31 2026 
-0.10
-0.15
Missed
Dec. 31 2025 
-0.02
-0.04
Missed
Sep. 30 2025 
-0.05
-0.04
Beat